Sort
48,018 grants matching “immunotherapy”
VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
$1,207,252Vanderbilt University · U01 · FY2002 · AI
TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8461 UNDER
$1,206,941Daniel Sullivan · H. Lee Moffitt Cancer Ctr & Res Inst · N01 · FY2009 · CA
ANTIGEN SPECIFIC THERAPY IN CNS AUTOIMMUNE DISEASES
$1,205,782Brigham And Women'S Hospital · P01 · FY2004 · NS
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
$1,205,769Brendan D Curti · Providence Portland Medical Center · R01 · FY2025 · CA
Pig-to-Monkey Islet Xenotransplantation
$1,205,659Bernhard Josef Hering · University Of Minnesota · U01 · FY2016 · AI
Immunotherapeutics Against Arenaviruses
$1,205,553Robert F Garry · Scripps Research Institute, The · U19 · FY2017 · AI
Monoclonal antibody-based intervention against SIV in nonhuman primates
$1,205,519Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$1,205,048Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2019 · AI
Immune modulation of radiation therapy with Flt3 ligand
$1,204,513Tibor Keler · Celldex Therapeutics, Inc. · R44 · FY2020 · CA
IN VIVO 31P MRS STUDIES OF NON-HODGKIN'S LYMPHOMA
$1,203,971Truman R. Brown · Columbia University Health Sciences · R01 · FY2009 · CA
Resource for Molecular Imaging Agents in Precision Medicine
$1,203,878Martin G Pomper · Johns Hopkins University · P41 · FY2019 · EB
Resource for Molecular Imaging Agents in Precision Medicine
$1,203,600Martin G Pomper · Johns Hopkins University · P41 · FY2020 · EB
Preclinical Development of a Thermostable Trivalent Filovirus Vaccine
$1,203,584Axel T Lehrer · University Of Hawaii At Manoa · R01 · FY2020 · AI
Immuno/Immunogene Therapies for Thoracic Malignancies
$1,203,367Steven Mark Albelda · University Of Pennsylvania · P01 · FY2009 · CA
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,202,994Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Novel Approach to High-Throughput Identification and Characterization of Neoantigen-Specific T-Cell Receptors to Guide Immunotherapy Development.
$1,202,794Magali Soumillon · Flexomics Llc · R44 · FY2022 · CA
Photodynamic Priming of Cancer and Image-guidance for Optimal Immune Response
$1,202,445Tayyaba Hasan · Massachusetts General Hospital · P01 · FY2023 · CA
Advanced pancreatic-immune organoid models of type 1 diabetes subtypes and therapeutic responses
$1,201,988Kevan C Herold · Yale University · UG3 · FY2025 · DK
Immuno/Immunogene Therapies for Thoracic Malignancies
$1,200,734Steven Mark Albelda · University Of Pennsylvania · P01 · FY2008 · CA
REGULATION OF ANTI-TUMOR IMMUNITY
$1,200,459Eckhard R Podack · University Of Miami School Of Medicine · P01 · FY2009 · CA
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
$1,200,301Douglas F Nixon · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · CA
Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles
$1,200,245Elias Sayour · University Of Florida · R01 · FY2025 · CA
Impact of tuberculosis on the development and function of the immune system in SIV-infected infants
$1,200,027Xiaolei Wang · Tulane University Of Louisiana · R01 · FY2019 · HD
OVERCOMING ANDROGEN RECEPTOR-MEDIATED PROSTATE CANCER RESISTANCE TO IMMUNOTHERAPY.
$1,200,000Northwestern University · · FY2021 · Defense Health Agency
SBIR Phase II: A digital platform to support food allergy oral immunotherapy treatments
$1,199,997Javier V Evelyn · Alerje, Inc. · · FY2023 · TIP